High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes

Journal of the American College of Cardiology

Volumn 58, Issue 5, 2011, Pages 467-473

  Bonello, Laurent ^a,b   Pansieri, Michel ^c   Mancini, Julien ^d,e   Bonello, Roland ^f   Maillard, Luc ^g   Barnay, Pierre ^c   Rossi, Philippe ^h   Ait Mokhtar, Omar ^a   Jouve, Bernard ⁱ   Collet, Frederic ^f   Peyre, Jean Pascal ^j   Wittenberg, Olivier ^k   De Labriolle, Axel ^l   Camilleri, Elise ^m   Cheneau, Edouard ⁿ   Cabassome, Elma ^a   Dignat George, Franoise ^b,o   Camoin Jau, Laurence ^b,o   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b INSERM   (France)

^c Hôpital d'Avignon   (France)

^d HÔpitaux de Marseille   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f Clinique Clairval   (France)

^g Clinique Axium   (France)

^h Clinique de Marignane   (France)

ⁱ Hôpital d'Aix en Provence   (France)

^j Service de Cardiologie   (France)

^k Clinique Beauregard   (France)

^l Clinique du Pont de Chaume   (France)

^m Hopital de Martigues   (France)

ⁿ Clinique Bouchard   (France)

^o HÔPITAL DE LA CONCEPTION   (France)

more..

Author keywords

antiplatelet therapy; high on treatment platelet reactivity; platelet monitoring; stent thrombosis; VASP index

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 79960603731     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.04.017     Document Type: Article

References (17)

1. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
2. P. Jremo, T.L. Lindahl, S.G. Fransson, and A. Richter Individual variations of platelet inhibition after loading doses of clopidogrel J Intern Med 252 2002 233 238
3. L. Bonello, U.S. Tantry, R. Marcucci Working Group on High On-Treatment Platelet Reactivity Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
4. D. Aradi, A. Komócsi, and A. Vorobcsuk Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis Am Heart J 160 2010 543 551
5. L. Bonello, L. Camoin-Jau, and S. Armero Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
6. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411 (Pubitemid 351447314)
7. PRINCIPLE-TIMI 44 Investigators Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
8. TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
9. A. Sugidachi, T. Ogawa, and A. Kurihara The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite J Thromb Haemost 5 2007 1545 1551 (Pubitemid 46965386)
10. TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial Eur Heart J 30 2009 1753 1763
11. D.E. Cutlip, S. Windecker, and R. Mehran Academic Research Consortium clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
12. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction J Am Coll Cardiol 50 2007 2173 2195
13. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schömig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients Initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
14. D. Sibbing, W. Koch, and D. Gebhard Cytochrome 2C19 (*)17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
15. W. Hochholzer, D. Trenk, and M.F. Fromm Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement J Am Coll Cardiol 55 2010 2427 2434
16. A.R. Hobson, Z. Qureshi, P. Banks, and N. Curzen Gender and responses to aspirin and clopidogrel: insights using short thrombelastography Cardiovasc Ther 27 2009 246 252
17. Price MJ. Gauging responsiveness with a VerifyNow assayimpact on thrombosis and safety. Presented at: Annual meeting of the American Heart Association; Chicago, IL; November 26, 2010.